Would you offer systemic therapy for BCLC Stage C HCC (portal vein invasion) following local therapy with Y90?  

Has the recent approval of atezolizumab/bevacizumab impacted your decision making? 



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Thomas Jefferson University Hospital
Overall, I agree with @Nguyen H. Tran. I think if ...
Medical Oncologist at Clinical Instructor
Thank you @Nguyen H. Tran and @Daniel Lin for your...
Sign in or Register to read more